Abstract
Background: Rivastigmine delays cognitive deterioration in patients with mild to moderate Alzheimer’s disease (AD). Treatment with rivastigmine results in beneficial effects on cognitive function, ADL performance, global function and behavior, when a daily dose of 6-12 mg is used for at least six months. However, the effect of rivastigmine on
... read more